ABSTRACT
We sought to identify maternal or clinical characteristics of women likely to develop preterm labor (PTL) at <34 weeks' gestation while receiving 17 α-hydroxyprogesterone caproate (17P) prophylaxis. Current singleton gestations with prior preterm delivery enrolled for outpatient 17P administration at <27 weeks' gestation were identified (n = 1177). Maternal and clinical characteristics were compared between women hospitalized and diagnosed with PTL at <34 weeks' gestation (PTL group, n = 270) and those without PTL (No PTL group, n = 660). PTL at <34 weeks' gestation occurred in 270/1177 (22.9%) of patients receiving 17P prophylaxis (mean gestational age at diagnosis was 28.3 ± 4.0 weeks). Recurrent preterm delivery occurred in 73.3% of women with PTL at <34 weeks. Maternal age, marital status, race, tobacco use, cerclage, gestational age at start of 17P, and Medicaid status were similar between the groups. Women developing PTL at <34 weeks were more likely to have >1 prior preterm delivery than those without PTL (35.2% versus 25.9%, p = 0.006, odds ratio [95% confidence interval] 1.5 [1.1, 2.1]). Women receiving 17P prophylaxis remain at increased risk for PTL and preterm birth. Patient education and surveillance for PTL symptoms may be warranted in women with a history of more than one prior preterm delivery.
KEYWORDS
Maternal risk factors - preterm labor - recurrent preterm delivery - 17 α-hydroxyprogesterone caproate (17P) - preterm birth prevention
REFERENCES
-
1 Martin J A, Hamilton B E, Sutton P D et al.. Births: final data for 2006. National Vital Statistics Reports; Vol. 57, No. 7 Hyattsville, MD; National Center for Health Statistics 2009
-
2
Goldenberg R L, Culhane J F, Iams J D, Romero R.
Epidemiology and causes of preterm birth.
Lancet.
2008;
371
75-84
-
3
Holbrook Jr R H, Laros Jr R K, Creasy R K.
Evaluation of a risk-scoring system for prediction of preterm labor.
Am J Perinatol.
1989;
6
62-68
-
4
American College of Obstetricians and Gynecologists .
ACOG Practice Bulletin No. 31. Assessment of risk factors for preterm birth. Clinical management guidelines for obstetrician-gynecologists. Number 31, October 2001. (Replaces Technical Bulletin number 206, June 1995; Committee Opinion number 172, May 1996; Committee Opinion number 187, September 1997; Committee Opinion number 198, February 1998; and Committee Opinion number 251, January 2001).
Obstet Gynecol.
2001;
98
709-716
-
5
Meis P J, Klebanoff M, Thom E National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network et al.
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
N Engl J Med.
2003;
348
2379-2385
-
6
Rouse D J, Caritis S N, Peaceman A M National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network et al.
A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins.
N Engl J Med.
2007;
357
454-461
-
7
Caritis S N, Rouse D J, Peaceman A M Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU) et al.
Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Obstet Gynecol.
2009;
113(2 Pt 1)
285-292
-
8
González-Quintero V H, Istwan N B, Rhea D J, Smarkusky L, Hoffman M C, Stanziano G J.
Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
J Matern Fetal Neonatal Med.
2007;
20
249-252
-
9
How H Y, Barton J R, Istwan N B, Rhea D J, Stanziano G J.
Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?.
Am J Obstet Gynecol.
2007;
197
260, e1-e4
-
10
Ventolini G, Duke J, Po W et al..
The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
J Reprod Med.
2008;
53
667-671
-
11
Rebarber A, Cleary-Goldman J, Istwan N B et al..
The use of 17 alpha-hydroxyprogesterone caproate (17p) in women with cervical cerclage.
Am J Perinatol.
2008;
25
271-275
-
12
Rittenberg C, Newman R B, Istwan N B, Rhea D J, Stanziano G J.
Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
J Reprod Med.
2009;
54
47-52
-
13
Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
Women receiving 17-α-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
Am J Obstet Gynecol.
2008;
199
389, e1-e4
-
14
Society for Maternal Fetal Medicine Publications Committee .
ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth.
Obstet Gynecol.
2008;
112
963-965
Saju JoyM.D. M.S.
Wake Forest University Health Sciences, Department of OB/GYN, Maternal-Fetal Medicine
Medical Center Boulevard, Winston-Salem, NC 27157, reprints are not available from the author.
Email: sjoy@wfubmc.edu